MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-31-2026
Adagene EBITDA per Share 2011-2026 | ADAG
Annual EBITDA per Share Adagene
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.63 | -0.42 | -1.53 | -1.42 | -2.65 | -1.21 | -1.08 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.42 | -2.65 | -1.28 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
-188 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-1.38 | - | 4.01 % | $ 150 M |  Canada |
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-5.25 | - | 1052.0 % | $ 415 M | USA |
 |
Albireo Pharma
ALBO
|
-6.41 | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
0.08 | - | - | $ 866 M |  China |
 |
ANI Pharmaceuticals
ANIP
|
3.54 | $ 81.6 | -0.49 % | $ 1.58 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Amgen
AMGN
|
23.9 | $ 342.65 | -0.08 % | $ 184 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
Aytu BioScience
AYTU
|
-0.39 | $ 2.63 | 1.74 % | $ 16.5 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-1.68 | $ 3.17 | -2.76 % | $ 7.63 B |  Australia |
 |
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | USA |
 |
PainReform Ltd.
PRFX
|
-7.2 | $ 0.68 | -4.45 % | $ 308 K |  Israel |
 |
Allena Pharmaceuticals
ALNA
|
-0.696 | - | 3.16 % | $ 1.9 M | USA |
 |
AVROBIO
AVRO
|
0.24 | - | 1083.1 % | $ 745 M | USA |
 |
Aptose Biosciences
APTO
|
0.05 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
-1.92 | - | -13.39 % | $ 1.45 M | USA |
 |
Biogen
BIIB
|
4.62 | $ 178.24 | 1.2 % | $ 26 B | USA |
 |
Brickell Biotech
BBI
|
-1.17 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Molecular Transport
AMTI
|
-3.2 | - | - | $ 10.1 M | USA |
 |
Beam Therapeutics
BEAM
|
-4.78 | $ 27.94 | -4.61 % | $ 2.3 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-8.25 | $ 225.36 | 0.63 % | $ 5 B |  Danmark |
 |
Athira Pharma
ATHA
|
-2.6 | - | - | $ 269 M | USA |
 |
Atreca
BCEL
|
0.14 | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
62.6 | $ 114.18 | -2.22 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
1.11 | $ 9.67 | 0.16 % | $ 1.52 B | Britain |
 |
Arrowhead Pharmaceuticals
ARWR
|
0.9 | $ 70.74 | 2.34 % | $ 9.46 B | USA |
 |
CASI Pharmaceuticals
CASI
|
-0.304 | $ 0.99 | -0.01 % | $ 135 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.08 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Catalyst Biosciences
CBIO
|
-1 | $ 9.63 | -5.08 % | $ 634 M | USA |
 |
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-0.87 | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-0.11 | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
-1.29 | - | -7.31 % | $ 87 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.01 | $ 4.05 | -1.22 % | $ 8.81 B | Israel |
 |
Amneal Pharmaceuticals
AMRX
|
1.01 | $ 13.65 | -3.3 % | $ 4.22 B | USA |
 |
AIkido Pharma
AIKI
|
-1.85 | - | 1.93 % | $ 17.4 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-2.34 | - | -74.18 % | $ 955 K | USA |
 |
Cerus Corporation
CERS
|
-0.07 | $ 2.32 | -0.22 % | $ 428 M | USA |
 |
CureVac N.V.
CVAC
|
-2.22 | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-1.56 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-1.72 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-44.1 | - | 4.14 % | $ 49.1 M | USA |